ClinicalTrials.gg
CompletedNCT02402712Updated Sep 6, 2019

Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer

A Phase 3 interventional study of Docetaxel and pertuzumab [Perjeta] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 112 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
37th of 248
418 · median 68
Started
2015
with 9 others
Phase 3
51 of 264
5 open now
Registered
217th of 264
by date
Lead sponsor
16 of 264
Hoffmann-La Roche

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 37th largest by enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2015, is one of 51 in phase 3, and was the 217th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, single-arm, multicenter, Phase IIIb study to evaluate the safety and tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in female patients with HER2-positive metastatic or locally recurrent breast cancer. Enrolled patients are to receive study medication until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end, whichever occurs first. The anticipated time on study treatment is approximately 24 months. The target sample size is 400.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed and documented adenocarcinoma of the breast with or locally recurrent disease not amenable to curative resection. Patients with measurable and/or non- evaluable according to (RECIST), Version 1.1 are eligible.
  • -positive disease (defined as either immunohistochemistry [IHC] 3 + or in situ hybridization [ISH] positive) as assessed by local laboratory on primary tumor or metastatic site if primary tumor not available
  • (ECOG) Performance Status 0 or 1
  • (LVEF) of at least 50%
  • Negative serum pregnancy test result at baseline and use of effective as defined by the protocol

Exclusion criteria

Exclusion Criteria:

  • Previous systemic non-hormonal anti-cancer therapy for the or locally recurrent disease. Note: Prior to study entry, up to two lines of hormonal therapy for metastatic or locally recurrent disease are permitted, one of which may be in combination with everolimus.
  • Disease-free interval of less than 6 months from completion of or neoadjuvant systemic non-hormonal treatment to recurrence of breast cancer
  • Previous approved or investigative anti- agents as neoadjuvant or adjuvant therapy for any breast cancer treatment, except Herceptin
  • History of persistent Grade 2 or higher hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
  • Radiographic evidence of central nervous system (CNS) metastases as assessed by computed tomography (CT) or magnetic resonance imaging (MRI), unless they have been treated and have been stable for at least 3 months and do not require ongoing treatment
  • Current peripheral neuropathy of Grade 3 or greater
  • History of other within the last 5 years prior to first dose of study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma
  • Inadequate organ function
  • Uncontrolled hypertension with or without medication
  • cardiovascular disease
  • History of decline to below 50% during or after prior Herceptin neo-adjuvant or adjuvant therapy
  • Current known infection with , virus, or virus
  • Severe uncontrolled concomitant disease that would contraindicate the use of any of the drugs used in this study or that would put the patient at high risk for treatment-related complications, including severe pulmonary conditions/illness
  • Pregnant or lactating women
  • Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy
  • History of receiving any investigational treatment within 28 days prior to first dose of study drug administration (dosing) or concurrent participation in any interventional clinical trial
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Herceptin SC + Perjeta IV + docetaxel IV

    Single arm

    Drug: Docetaxel · Drug: pertuzumab [Perjeta] · Drug: trastuzumab [Herceptin]

Interventions

  • Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.

  • Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg

    Also known as: RO4368451

  • Subcutaneous administration of 600 mg/5 mL every 3 weeks

    Also known as: RO0452317

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to 24 months after the last patient has been enrolled, approximately 3.5 years

  2. Incidence and severity of adverse events Grade >/= 3, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0

    Time frame: Up to 24 months after the last patient has been enrolled, approximately 3.5 years

  3. Incidence of cardiac events (composite outcome measure): congestive heart failure (CHF) and cardiac death

    Time frame: Up to 24 months after the last patient has been enrolled, approximately 3.5 years

Secondary outcomes

  1. Progression-free survival, tumor assessments according to RECIST v1.1

    Time frame: Up to 3.5 years

  2. Overall survival

    Time frame: Up to 3.5 years

  3. Objective response rate, defined as a complete response (CR) or a partial response (PR)

    Time frame: Up to 3.5 years

  4. Incidence of anti-Herceptin, anti-rHuPH20 antibodies

    Time frame: Up to 3.5 years

07

Study locations

112 sites
  • AZ Sint Jan
    Brugge, 8000, Belgium
  • UZ Brussel
    Brussel, 1090, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • Clinique Saint-Joseph
    Liège, 4000, Belgium
  • Sint Augustinus Wilrijk
    Wilrijk, 2610, Belgium
  • Multiprofile Hospital For Active Treatment Dr. Tota Venkova JSC
    Gabrovo, 5300, Bulgaria
  • Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
    Plovdiv, 4000, Bulgaria
  • University Multiprofile Hospital for Active Treatment Sveti Georgi EAD
    Plovdiv, 4002, Bulgaria
  • Comprehensive Cancer Center-Plovdiv
    Plovdiv, 4004, Bulgaria
  • Specialized Hospital for Active Treatment of Oncological Diseases - Sofia District EOOD
    Sofia, 1233, Bulgaria
  • Specialized Hospital for Active Cancer Treatment, Dr. Mark Antonov Markov - Varna Ltd
    Varna, 9010, Bulgaria
  • MDOZS Vrasta Ltd.
    Vratsa, 3000, Bulgaria
  • Moncton Hospital
    Moncton, New Brunswick E1C 6Z8, Canada
  • Royal Victoria Regional Health Centre
    Barrie, Ontario L4M 6M2, Canada
  • Centre Hospitalier Regional Metz-Thionville - Hopital de Mercy
    Ars-Laquenexy, 57530, France
  • Medipole De Savoie; Departement Oncologie
    Challes Les Eaux, 73190, France
  • Hopital Prive Sainte Marie
    Chalon sur Saone, 71100, France
  • Centre Hospitalier Louis Pasteur
    Chartes Le Coudray, 28630, France
  • Pole Sante Republique; Pharmacie Oncologique
    Clermont Ferrand, 63050, France
  • Centre Georges Francois Leclerc
    Dijon, 21000, France
  • Groupe Hospitalier Mutualiste de Grenoble
    Grenoble Cedex, 38028, France
  • CHU de Grenoble
    Grenoble, 38043, France
  • Hopital Europeen
    Marseille, 13003, France
  • Centre Hospitalier de Mont de Marsan - Hopital Layne
    Mont De Marsan, 40024, France
  • Hopital Saint Joseph; Service de Rhumatologie
    Paris, 75674, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • Strasbourg Oncologie Libérale
    Strasbourg, 67000, France
  • Gustave Roussy
    Villejuif CEDEX, 94800, France
  • Studienzentrum Aschaffenburg
    Aschaffenburg, 63739, Germany
  • Onkologische Schwerpunktpraxis Dr. Joerg Schilling
    Berlin, 10317, Germany
  • Universitaetsklinikum Erlangen
    Erlangen, 91054, Germany
  • Kliniken Essen-Mitte
    Essen, 45136, Germany
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
    Freiburg, 79110, Germany
  • Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I
    Lubeck, 23538, Germany
  • Onkologische Schwerpunktpraxis Lübeck
    Lübeck, 23562, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55101, Germany
  • Suedharz Klinikum Nordhausen gGmbH
    Nordhausen, 99734, Germany
  • Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe
    Offenbach, 63069, Germany
  • Johanniter-Krankenhaus Genthin - Stendal GmbH; Gynäkologie und gynäkologische Onkologie
    Stendal, 39576, Germany
  • Klinikum Mutterhaus der Borromaeerinnen
    Trier, 54290, Germany
  • Universitätsklinikum Würzburg
    Wuerzburg, 97080, Germany
  • Szent Margit Hospital; Dept. of Oncology
    Budapest, 1032, Hungary
  • Ogyi, Orszagos Gyogyszereszeti Intezet
    Budapest, 1051, Hungary
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Szent Imre Egyetemi Oktatokorhaz
    Budapest, 1115, Hungary
  • Orszagos Onkologiai Intezet
    Budapest, 1122, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely
    Budapest, H-1077, Hungary
  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház
    Miskolc, 3526, Hungary
  • Azienda Ospedaliera Regionale San Carlo
    Potenza, Basilicata 85100, Italy
  • Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori
    Meldola, Emilia-Romagna 47014, Italy
  • Azienda Ospedaliero - Universitaria di Modena Policlinico
    Modena, Emilia-Romagna 41110, Italy
  • Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova
    Reggio Emilia, Emilia-Romagna 42123, Italy
  • Ospedale Infermi di Rimini
    Rimini, Emilia-Romagna 47900, Italy
  • Istituti Fisioterapici Ospitalieri
    Roma, Lazio 00144, Italy
  • Ospedale Policlinico San Martino
    Genova, Liguria 16132, Italy
  • Asst Papa Giovanni XXIII
    Bergamo, Lombardia 24100, Italy
  • Istituto Europeo Di Oncologia
    Milano, Lombardia 20141, Italy
  • Istituto Clinico Humanitas
    Rozzano (MI), Lombardia 20089, Italy
  • Asst Della Valtellina E Dell'Alto Lario
    Sondrio, Lombardia 23100, Italy
  • Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele
    Catania, Sicilia 95123, Italy
  • Ospedale Santa Maria Annunziata
    Bagno A Ripoli, Toscana 50012, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, Toscana 50141, Italy
  • Azienda USL 5 di Pisa
    Pisa, Toscana 56100, Italy
  • Ospedale Santo Stefano, Azienda USL Centro Prato
    Prato, Toscana 59100, Italy
  • Azienda Ospedaliera Santa Maria di Terni
    Terni, Umbria 20089, Italy
  • Azienda Ospedaliero-Universitaria di Ferrara, Arcispedale Sant'Anna
    Cona (Ferrara), Veneto 44124, Italy
  • Ospedale Sacro Cuore Don Calabria
    Negrar, Veneto 37024, Italy
  • IOV - Istituto Oncologico Veneto IRCCS
    Padova, Veneto 35128, Italy
  • "Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento"
    Verona, Veneto 37124, Italy
  • Consultorio de Medicina Especializada
    Mexico, Mexico CITY (federal District) 03100, Mexico
  • Grupo Medico Camino
    DF, 03310, Mexico
  • Superare Centro de Infusion S.A. de C.V.
    Mexico, 06760, Mexico
  • Fundacion de Cancer de Mama.A.C.
    Mexico, Mexico
  • Centro Medico San Jose
    Monterrey, Nuevo Leon, 64710, Mexico
  • Cancerología
    Queretaro, 76090, Mexico
  • Bialostockie Centrum Onkologii im. Marii Sklodowskiej - Curie
    Bialystok, 15-027, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii
    Gdansk, 80-219, Poland
  • Szpitale Pomorskie Sp. z o. o.
    Gdynia, 81-519, Poland
  • Przychodnia Lekarska KOMED
    Konin, 625000, Poland
  • Szpital Uniwersytecki w Krakowie
    Krakow, 31-501, Poland
  • Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli
    Lublin, 20-090, Poland
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej MSW z W-MCO w Olsztynie
    Olsztyn, 10-228, Poland
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Opolskie Centrum Onkologii
    Opole, 45-061, Poland
  • Szpital Kliniczny; Przemienienia Panskiego;Uniwersytetu Medyczny im.; Karola Marcinkowskiego w Pozna
    Poznan, 60-569, Poland
  • Wielkopolskie Centrum Onkologii
    Poznan, 61-866, Poland
  • Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie; Klinika Onkologiczna
    Warsaw, 00-973, Poland
  • MAGODENT Sp. z o.o.
    Warsaw, 04-125, Poland
  • Hospital de Braga
    Braga, 4710-243, Portugal
  • Instituto Portugues Oncologia de Coimbra Francisco Gentil, EPE
    Coimbra, 3000-075, Portugal
  • Hospital da Luz
    Lisboa, 1500-650, Portugal
  • Centro Hospitalar de Lisboa Norte, EPE - Hospital Santa Maria
    Lisboa, 1649-035, Portugal
  • IPO do Porto; Servico de Oncologia Medica
    Porto, 4200-072, Portugal
  • Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clinico Universitario
    Santiago de Compostela, LA Coruña 15706, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14004, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28040, Spain

Showing the first 100 of 112 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Kuemmel S, Tondini CA, Abraham J, Nowecki Z, Itrych B, Hitre E, Karaszewska B, Juarez-Ramiro A, Morales-Vasquez F, Perez-Garcia JM, Cardona-Huerta S, Monturus E, Sequi M, Restuccia E, Benyunes M, Martin M. Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Cancer Res Treat. 2021 Jun;187(2):467-476. doi: 10.1007/s10549-021-06145-3. Epub 2021 Mar 21. PubMed 33748921 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Feb 2019, 45 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 45 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2015
First posted
Mar 30, 2015
StartActual
May 6, 2015
Primary completionActual
Feb 22, 2019
CompletionActual
Feb 22, 2019
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02402712
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 30, 2015
Start date
May 6, 2015
Primary completion
Feb 22, 2019
Completion
Feb 22, 2019
Last update
Sep 6, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Trastuzumab

Start the discussion